Predictive Oncology (POAI)
(Delayed Data from NSDQ)
$1.51 USD
-0.15 (-9.04%)
Updated Apr 26, 2024 03:58 PM ET
After-Market: $1.63 +0.12 (7.95%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Predictive Oncology Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 2 | 1 | 1 | 1 |
Cost Of Goods | 1 | 1 | 0 | 0 | 1 |
Gross Profit | 1 | 1 | 1 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 15 | 27 | 21 | 13 | 15 |
Income After Depreciation & Amortization | -14 | -26 | -20 | -12 | -14 |
Non-Operating Income | 0 | 0 | 0 | -13 | -6 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -14 | -26 | -20 | -26 | -19 |
Income Taxes | 0 | 0 | -1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -14 | -26 | -20 | -26 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -14 | -26 | -20 | -26 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -13 | -21 | -15 | -10 | -11 |
Depreciation & Amortization (Cash Flow) | 1 | 5 | 6 | 2 | 3 |
Income After Depreciation & Amortization | -14 | -26 | -20 | -12 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.02 | 3.65 | 2.74 | 0.60 | 0.14 |
Diluted EPS Before Non-Recurring Items | -3.48 | -5.00 | -4.60 | -28.60 | -84.00 |
Diluted Net EPS (GAAP) | -3.48 | -7.00 | -7.20 | -44.20 | -137.20 |
Fiscal Year end for Predictive Oncology Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.34 | 0.72 | 0.49 | 0.24 |
Cost Of Goods | NA | 0.25 | 0.11 | 0.16 | 0.12 |
Gross Profit | NA | 0.09 | 0.61 | 0.33 | 0.12 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.59 | 3.76 | 4.29 | 3.58 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.50 | -3.15 | -3.96 | -3.46 |
Non-Operating Income | NA | 0.03 | -0.01 | 0.04 | 0.04 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -3.48 | -3.16 | -3.92 | -3.42 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.48 | -3.16 | -3.92 | -3.42 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.48 | -3.16 | -3.92 | -3.42 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 4.09 | 4.03 | 4.00 | 3.97 |
Diluted EPS Before Non-Recurring Items | NA | -0.85 | -0.78 | -0.95 | -0.86 |
Diluted Net EPS (GAAP) | NA | -0.86 | -0.78 | -0.98 | -0.86 |